Virtu KCG Holdings’s Axsome Therapeutics AXSM Stock Holding History

Virtu KCG Holdings’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12,631	Closed	-$49K	–	2880
2017 Q1	$49K	Buy	+12,631	New	+$60.4K	﹤0.01%	2847

Other funds holding AXSM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Virtu KCG Holdings's AXSM Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Axsome Therapeutics (AXSM) in Q2 2017, closing a stake of 12,631 shares — an estimated $49K sold.

Virtu KCG Holdings first reported a position in AXSM in Q1 2017 and held it in 1 quarter. The position peaked at $49K in Q1 2017. 35 funds tracked by Wall St. Rank hold AXSM as of Q2 2017.

Virtu KCG Holdings reported no remaining Axsome Therapeutics position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 12,631 Axsome Therapeutics shares in Q2 2017, an estimated $49K.
Virtu KCG Holdings first reported a position in Axsome Therapeutics in Q1 2017 and held it in 1 quarter.
Virtu KCG Holdings's Axsome Therapeutics position peaked at $49K in Q1 2017.
35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.